Stealth BioTherapeutics Announces Oral Presentation of New Duchenne Muscular Dystrophy Data at the 2022 Muscular Dystrophy Association Clinical and Scientific Conference

Rhea-AI Summary

Stealth BioTherapeutics Corp (Nasdaq: MITO) announced an oral presentation at the 2022 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, scheduled for March 13-16, 2022, in Nashville, Tennessee. The presentation will discuss how elamipretide may enhance the therapeutic effects of an exon skipping PMO in a mouse model of X-linked muscular dystrophy. Reenie McCarthy, CEO, expressed optimism about advancing clinical development to improve treatments for Duchenne muscular dystrophy.

Positive

• Presentation of data indicating elamipretide's potential to enhance dystrophin expression.
• Opportunity to advance clinical development for treating Duchenne muscular dystrophy.

Negative

• None.

BOSTON, Feb. 8, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company will have an oral presentation at the upcoming 2022 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference, being held March 13-16, 2022 in Nashville, Tennessee. The presentation showcases data demonstrating a potential relationship between elamipretide and an exon skipping phosphorodiamidate morpholino oligomer (PMO) in the X-linked muscular dystrophy (mdx) mouse model.  PMOs are one of the few approved drug classes for the treatment of patients with Duchenne muscular dystrophy (DMD).

The presentation details are as follows:

Title: The mitochondria-targeting peptide elamipretide potentiates dystrophin expression induced by an exon-skipping morpholino in the mdx mouse model
Presenter: David A. Brown, Ph.D.
Date: Wednesday, March 16, 2022
Time: 9:10-9:25 am CST
Location: Gaylord Opryland Resort & Convention Center Hermitage AB Room

"We are encouraged to learn that administration of elamipretide in addition to standard-of-care therapy may amplify therapeutic benefit in this model of Duchenne muscular dystrophy," said Reenie McCarthy, Chief Executive Officer of Stealth.  "With this finding, we hope to commence additional clinical development efforts with an ultimate goal of improving the standard of care for individuals suffering from the neuromuscular, as well as the cardiomyopathic, symptoms of this devastating and life-limiting disease."

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the eye, the neuromuscular system, the heart and the brain. We believe our lead product candidate, elamipretide, has the potential to treat ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration, rare neuromuscular disorders, such as primary mitochondrial myopathy caused by nuclear DNA mutations and DMD, and rare cardiomyopathies, such as Barth syndrome. We are evaluating our second-generation clinical-stage candidate, SBT-272, for rare neurological disease indications, such as amyotrophic lateral sclerosis and frontotemporal dementia, following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.

Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-oral-presentation-of-new-duchenne-muscular-dystrophy-data-at-the-2022-muscular-dystrophy-association-clinical-and-scientific-conference-301476934.html

SOURCE Stealth BioTherapeutics Inc.

FAQ

What is the focus of the Stealth BioTherapeutics presentation at the MDA Conference?

The presentation focuses on data regarding elamipretide's potential relationship with PMOs in a mouse model of Duchenne muscular dystrophy.

When will Stealth BioTherapeutics present its findings at the MDA Conference?

Stealth BioTherapeutics will present its findings on March 16, 2022, from 9:10 to 9:25 am CST.

What are the implications of the elamipretide findings for Duchenne muscular dystrophy?

The findings suggest that elamipretide may enhance the therapeutic benefits of standard care in Duchenne muscular dystrophy.

What is the significance of the 2022 MDA Clinical and Scientific Conference for Stealth BioTherapeutics?

The conference provides a platform for presenting significant data on elamipretide, potentially attracting attention for further clinical development.